Metronidazole ointment - Braintree Laboratories

Drug Profile

Metronidazole ointment - Braintree Laboratories

Alternative Names: BLI-1300

Latest Information Update: 17 Sep 2015

Price : $50

At a glance

  • Originator Braintree Laboratories
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Crohn's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 25 Oct 2012 Braintree Laboratories terminates a phase II trial in Chrohn's disease in USA (NCT01442363)
  • 23 Nov 2011 Phase-II clinical trials in Crohn's disease in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top